Volume 97, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Clinical trials are challenging endeavors. Planning and implementing an investigational vaccine trial in Liberia, in the midst of an Ebola virus disease (EVD) epidemic that World Health Organization classified a public health emergency of international concern, presented extraordinary challenges. Normally, years of preparation and a litany of tasks lay the groundwork for a successful, randomized, blinded, placebo-controlled trial focused on safety and efficacy. Difficult research settings, unpredictable events, and other unique circumstances can add complexity. The setting in Liberia was especially problematic due to an infrastructure still badly damaged following a lengthy civil war and a very fragile health-care system that was further devastated by the EVD outbreak. The Partnership for Research on Vaccines in Liberia I EVD vaccine trial was planned and implemented in less than 3 months by a Liberian and U.S. research partnership, and its Phase II substudy was fully enrolled 3 months later. Contrasting conventional wisdom with trial outcomes offers an opportunity to compare early assumptions, barriers encountered, and adaptive strategies used, with end results. Understanding what was learned can inform future trial responses when disease outbreaks, especially in resource-poor locations with minimal infrastructure, pose a significant threat to public health.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

Loading full text...

Full text loading...



  1. WHO, August 8, 2014. Statement on the 1st Meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in West Africa. Available at: http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/. Accessed September 7, 2016.
  2. WHO, August 8, 2014. Ebola Virus Disease Update: West Africa. Available at: http://www.afro.who.int/en/clusters-a-programmes/dpc/epidemic-a-pandemic-alert-and-response/outbreak-news/4241-ebola-virus-disease-west-africa-8-august-2014.html. Accessed September 7, 2016.
  3. Republic of Liberia, 2014. President Ellen Johnson Sirleaf to President Barrack H. Obama. Available at: http://www.allafrica.com/view/resource/main/main/id/00090375.html. Accessed September 9, 2016.
  4. WHO, October 23, 2014. WHO High-Level Meeting on Ebola Vaccines Access and Financing. Available at: http://apps.who.int/iris/bitstream/10665/137184/1/WHO_EVD_Meet_EMP_14.2_eng.pdf. Accessed September 7, 2016.
  5. Scientific and Technological Cooperation; Response to Ebola. Agreement between the United States of America and Liberia, November 19, 2014. Available at: http://www.state.gov/documents/organization/261090.pdf. Accessed September 10, 2016.
  6. PREVAIL, January 30, 2015. Version 1.0. NIAID Protocol Number 15-I-N071, US Project Assurance FWA0005897, Liberian Ministry of Health and Social Welfare Project Assurance FWA00021658.
  7. WHO Ebola response team, 2014. Ebola virus disease in west Africa: the first 9 months of the epidemic and forward projections. N Engl J Med 371: 14811495.[Crossref]
  8. CDC, 2014. Estimating the future number of cases in the Ebola epidemic—Liberia and Sierra Leone, 2014–2015. MMWR 63: 114. Available at: https://www.cdc.gov/mmwr/pdf/other/su6303.pdf. Accessed February 22, 2016.
  9. Kennedy SB, Neaton JD, Lane HC, Kieh MWS, Massaquoi MBF, Touchette NA, Nason MC, Follman DA, Boley FK, Johnson MP, Larson G, Kateh FN, Nyenswah TG, , 2016. Implementation of an Ebola virus disease vaccine vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and change. Clin Trials 13: 4956.[Crossref]
  10. PREVAIL, March 31, 2015. Version 2.0. NIAID Protocol Number 15-I-N071, US Project Assurance FWA0005897. Liberian Ministry of Health and Social Welfare Project Assurance FWA00021658.
  11. Nyenswah T, , 2016. Leadership in times of crisis: a personal reflection from the center of the Ebola epidemic response in Liberia. Health Systems and Reform 2: 208212.[Crossref]
  12. Klimt CR, , 1981. The conduct and principles of randomized clinical trials. Control Clin Trials 2: 283293.[Crossref]
  13. Doe-Anderson J, Baseler B, Driscoll P, Johnson M, Lysander J, McNay L, Njoh WS, Smolskis M, Wehrlen L, Zukerman J, PREVAIL I Study Group, 2016. Beating the odds: successful establishment of a Phase II/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak. Contemp Clin Trials 4: 6873.[Crossref]
  14. WHO, 2014. Ebola Response Roadmap Situation Report. Available at: http://www.who.int/csr/disease/ebola/situation-reports/archive/en/. Accessed October 4, 2016.
  15. Cohen J, Kupferschmidt K, , 2014. Ebola vaccine trials raise ethical issues, randomized studies may offer fastest answer. Science 346: 289290.[Crossref]
  16. Halsey ES, , 2016. An outbreak of fearsome photos and headlines: Ebola and local newspapers in west Africa. Am J Trop Med Hyg 95: 988992.[Crossref]
  17. Folayan MO, Peterson K, Kombe F, , 2015. Ethics, emergencies and Ebola clinical trials: the role of governments and communities in offshored research. Pan Afr Med J 22 (Suppl 1): 10.
  18. Rid A, Emanuel E, , 2014. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet 384: 18961899.[Crossref]
  19. Folayan MO, Haire BG, , 2015. Ethical considerations in the conduct of research on therapies for the prevention and treatment of Ebola virus disease in developing countries. Pan Afr Med J 22 (Supp 1): 8.
  20. Liberia Medicines and Health Products Regulatory Authority, 2014. Guideline for Application to Conduct of Clinical Trials in Liberia, 1st edition. Monrovia, Liberia: Authority.
  21. US NIAID, NIH, 2016. Clinical Regs: Liberia, Ethics Committee. Available at: https://clinregs.niaid.nih.gov/single_country.php?c_id=122. Accessed February 22, 2017.
  22. Massaquoi MBF, Kennedy SB, Tegli JK, Bolay FK, Kateh FN, , 2016. Fostering collaboration on post-Ebola clinical research in Liberia. Lancet Glob Health 4: e239.[Crossref]
  23. Lane HC, Marston HD, Fauci AS, , 2016. Conducting clinical trials in outbreak settings: points to consider. Clin Trials 13: 9295.[Crossref]
  24. Onishi N, Fink S, , 2015. Vaccines Face Same Mistrust that Fed Ebola. New York Times, 13 March. Available at: http://nyti.ms/1F9htLk. Accessed October 20, 2016.
  25. UN, 2014. Per Capita GDP at Current Prices: US Dollars. Available at: http://data.un.org/Search.aspx?q=GDP+per+capita. Accessed October 17, 2016.
  26. Dance S, , 2014. Volunteers Sign up for Ebola Vaccine Trial at UM School of Medicine. Baltimore Sun 25. Available at: http://www.baltimoresun.com. Accessed September 15, 2016.
  27. Barrett C, Ward A, , 2014. Volunteers Sought for Human Trials of Ebola Vaccine. Financial Times, 5 September. Available at: http://www.ft.com. Accessed September 15, 2016.
  28. University of Geneva, 2014. The VSV Ebola Vaccine Study: Facts on the VSV-ZEBOV Vaccine Clinical Study. Fact sheet—Study v1.2. Available at: http://www.hug-ge.ch/sites/interhug/files/structures/centre_vaccinologie/documents/vsv-zebov-clinical-study-fact-sheet.pdf. Accessed September 15, 2016.
  29. Grady C, , 2005. Payment of clinical research subjects. J Clin Invest 115: 16811687.[Crossref]
  30. Wilkinson M, Moore A, , 1999. Inducements revisited. Bioethics 13: 114130.[Crossref]
  31. UNICEF, 2008. At a Glance: Liberia Statistics. Available at: https://www.unicef.org/infobycountry/liberia_statistics.html. Accessed February 2, 2017.
  32. US CIA. World Factbook—Liberia. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/li.html. Accessed February 2, 2017.
  33. Yates BC, Dodendorf D, Lane J, LaFramboise L, Pozehl B, Duncan K, Knodel K, , 2009. Testing an alternate informed consent process. Nurs Res 58: 135139.[Crossref]
  34. Daily Observer, 2015. Vp Boakai Acknowledges Amb Malac’s Role in Liberia Ebola Fight, 2 February. 1:55 admin1. Available at: http://liberianobserver.com/columns-health/vp-boakai-acknowledges-amb-malac’s-role-liberia-ebola-fight. Accessed November 3, 2016.
  35. US NIH, 2015. News Release 36: Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial. Available at: https://www.nih.gov/news-events/news-releases/ebola-test-vaccines-appear-safe-phase-2-liberian-clinical-trial. Accessed November 10, 2016.
  36. US FDA, September 2013. Guidance for Industry, Electronic Source Data in Clinical Investigations. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm328691.pdf. Accessed February 2, 2017.
  37. Onishi N, , 2014. Clashes Erupt as Liberia Sets an Ebola Quarantine. New York Times, 20 August. Available at: https://www.nytimes.com/2014/08/21/world/africa/ebola-outbreak-liberia-quarantine.html. Accessed September 23, 2016.
  38. Steinbrook R, , 2006. Compensation for injured research subjects. N Engl J Med 354: 18711873.[Crossref]
  39. Gostin LO, Friedman EA, , 2015. A retrospective and prospective analysis of the west African Ebola virus disease epidemic: robust national health systems at the foundation and an empowered WHO at the apex. Lancet 385: 19021909.[Crossref]
  40. Evans DK, Goldstein M, Popova A, , 2015. The Next Wave of Deaths from Ebola? The Impact of Health Care Worker Mortality. World Bank Group Policy Research working paper No. WPS 7344. Washington, DC: World Bank.
  41. CDC, 2016. Outbreaks Chronology: Ebola Virus Disease, 14 April . Available at: http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html. Accessed November 11, 2016.

Data & Media loading...

  • Received : 22 Dec 2016
  • Accepted : 04 Mar 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error